Abstract
Background Diabetes risk scores include age, waist circumference, body mass index, hypertension, use of blood pressure medication, and metabolic and lifestyle variables. Although patients with major depressive disorder have a higher risk of diabetes, none of the diabetes risk scores includes high risk of depression as an additional item.
Aim To validate three diabetes risk scores (FINDRISC, DESIR, ADA) in the Spanish population aged >45 years with the aim of predicting diabetes and to test the value of adding high risk of depression, defined as a PHQ-9 questionnaire score ≥10, to the risk score with the best discriminative performance.
Methods Prospective population-based cohort study in Madrid (Spain). FINDRISC, DESIR, ADA, PHQ-9, and OGTT values were measured at baseline. Participants with OGTT <200 mg/dl (n= 1,242) were followed up for a median of 7.3 years using their general practitioner’s electronic health record (EHR) and telephone contact. Incident diabetes was identified as treatment for diabetes, fasting plasma glucose ≥126 mg/dl, a new diagnosis in the EHR, or self-reported diagnosis. At the end of the study, the performance of diabetes risk scores, including a modified original FINDRISC score with a new variable for high risk of depression (FINDRISC-MOOD), was assessed.
Results During follow-up, 104 (8.4%; 95% CI, 6.8-9.9) participants developed diabetes, and 185 had a PHQ-9 score ≥10. The AUROC values were 0.70 (95% CI, 0.67-0.72) for FINDRISC-MOOD and 0.68 (95% CI, 0.65-0.71) for the original FINDRISC. The AUROC for DESIR and ADA were 0.66 (95% CI, 0.63-0.68) and 0.66 (95% CI, 0.63-0.69), respectively. There were no significant differences in the AUROC between FINDRISC-MOOD and the remaining scores.
Conclusion FINDRISC-MOOD performed slightly better than the other risk scores, although the differences were not significant. FINDRISC-MOOD could be used to identify the risk of future diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Instituto de Salud Carlos III grant numbers PI15/00259, PI18/01025, and PI22/01499 and was by the European Union.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of HHospital Carlos III gave ethical approval for this work Ethics committee/IRB of Hospital Universitario La Paz gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available upon reasonable request
